Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Fineline Cube Jul 30, 2026
Company Deals

China Resources Pharmaceutical to Acquire Lier Chemical for $795M in Strategic Move into Agrochemical Sector

Fineline Cube Jul 30, 2026
Company Deals

TPMeds Secures Tens of Millions in RMB Angel Round Led by Lotus Lake Ventures to Advance TPM004 IND and PepTetris Platform

Fineline Cube Jul 29, 2026
Company Deals

HBM and Sinopharm Form Innovation Consortium to Accelerate Fully Human Antibody Development Across Oncology and Inflammatory Diseases

Fineline Cube Jul 28, 2026
Company Deals

China Medical System’s Rxilient Secures Exclusive Southeast Asia Rights to Polichem’s Finjuve and Ciclopoli Dermatology Portfolio

Fineline Cube Jul 28, 2026
Policy / Regulatory

China’s CDE Tightens Drug Review Standards with New “No Supplemental Data” Rule for Major Deficiencies

Fineline Cube Jul 29, 2026
Company Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Fineline Cube Jul 30, 2026
Company Drug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Fineline Cube Jul 30, 2026
Company Drug

Shanghai Henlius Biotech’s HLX22 Receives NMPA Approval for Phase II HER2-Targeted Study

Fineline Cube Dec 5, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...

Company Deals

Jiangsu Recbio Technology Secures Private Placement with Yangtze River Pharmaceutical for Vaccine Development

Fineline Cube Dec 5, 2024

China-based Jiangsu Recbio Technology Co., Ltd (HKG: 2179) has successfully placed 142 million shares through...

Company Deals

Hangzhou Chance Pharmaceuticals Partners with Yiling Pharmaceutical for Inhalation Powder Development

Fineline Cube Dec 5, 2024

China’s Hangzhou Chance Pharmaceuticals Co., Ltd., a specialist in lung drug delivery, has entered into...

Company Deals

GRIT Biotechnology and Vitalgen BioPharma Partner on CRISPR-AaCas12bMAX Cell Therapies

Fineline Cube Dec 5, 2024

China-based cell therapy specialists GRIT Biotechnology and Shanghai Vitalgen BioPharma Co., Ltd have entered into...

Company Deals

YiChang HEC ChangJiang Pharmaceutical and DP Technology Deepen Partnership with AI Focus

Fineline Cube Dec 5, 2024

China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has announced a comprehensive partnership with...

Company Deals

Mabwell Bioscience Enters Licensing Agreement for Biosimilar Denosumab in Peru

Fineline Cube Dec 5, 2024

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced a licensing agreement with its...

Company Deals

Analytical BioSciences Sells Global Rights to Pre-Clinical Anti-Tumor Drugs to Gilead

Fineline Cube Dec 4, 2024

Sino-US firm Analytical BioSciences Limited has entered into an asset purchase agreement with Gilead (NASDAQ:...

Company Deals

CanSino Biologics Partners with Etana for Inhaled Tuberculosis Vaccine Development

Fineline Cube Dec 4, 2024

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has entered into a strategic partnership with Indonesia-based...

Company Deals

Zhida Pharma Secures Licensing Deal for Vivesto AB’s Apealea in China

Fineline Cube Dec 4, 2024

Zhejiang-based Zhida Pharma has announced a licensing deal with Sweden-headquartered Vivesto AB (STO: VIVE), securing...

Company Deals

Guangzhou Innogen Pharmaceutical Files for IPO on Hong Kong Stock Exchange

Fineline Cube Dec 4, 2024

Guangzhou Innogen Pharmaceutical Group Co., Ltd., a China-based pharmaceutical company, has made an initial public...

Company Deals

Coherus BioSciences Sells Udenyca Franchise to Intas Pharmaceuticals in Asset Purchase Deal

Fineline Cube Dec 4, 2024

US-based Coherus BioSciences, Inc. (Coherus, NASDAQ: CHRS) has announced an asset purchase agreement with Indian-headquartered...

Company Deals Drug

GSK plc Enters Exclusive Option Agreement with Duality Biologics for ADC Candidate DB-1324

Fineline Cube Dec 4, 2024

UK-based GSK plc (NYSE: GSK) has entered into an exclusive option agreement with Duality Biologics,...

Company Deals

Keros Therapeutics and Takeda Enter Licensing Agreement for Elritercept Development

Fineline Cube Dec 4, 2024

US-based Keros Therapeutics, Inc. (NASDAQ: KROS) has announced a significant licensing agreement with Japan-headquartered Takeda...

Company Deals

Gilead Sciences Secures Exclusive Option for Tubulis’ Tubutecan and Alco5 Platforms to Develop ADC

Fineline Cube Dec 4, 2024

US-based Gilead Sciences Inc., (NASDAQ: GILD) has announced an exclusive option and license agreement with...

Company Deals

Ophthalmology Biotech Cloudbreak Pharma Inc. Pursues Hong Kong IPO

Fineline Cube Dec 4, 2024

Cloudbreak Pharma Inc., a Cayman Island-registered ophthalmology biotech company, has filed for an initial public...

Company Deals

COUR Pharmaceutical Enters Licensing Agreement with Genentech for Autoimmune Disease Treatment

Fineline Cube Dec 4, 2024

US-based COUR Pharmaceutical has announced a strategic collaboration and licensing agreement with Genentech, a member...

Company Drug

Guangzhou Virotech’s Oncolytic Virus M1 Receives Tacit Clinical Approval from NMPA

Fineline Cube Dec 4, 2024

Guangzhou Virotech Pharmaceutical Co., Ltd., a China-based pharmaceutical company, has announced receiving tacit clinical approval...

Company Deals Drug

Ipsen Secures Global Licensing Agreement for Biomunex Pharmaceuticals’ BMX-502 T Cell Engager

Fineline Cube Dec 4, 2024

France-based Ipsen (OTCMKTS: IPSEY) has announced a significant global licensing agreement with compatriot firm Biomunex...

Company Drug

OncoC4, Inc. Receives FDA Clearance for AI-081, a PD-1 and VEGF Bispecific Antibody

Fineline Cube Dec 4, 2024

US-based OncoC4, Inc. has announced that it has received clinical clearance from the US Food...

Company Drug

Luye Pharma’s Zepzelca Receives NMPA Approval for Metastatic Small Cell Lung Cancer Treatment

Fineline Cube Dec 4, 2024

China-based Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from...

Posts pagination

1 … 289 290 291 … 701

Recent updates

  • Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease
  • Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements
  • Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression
  • Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares
  • CSPC Pharmaceutical’s Nectin-4 Targeting ADC CRB-701 Receives FDA Approval for Registrational Trial in Second-Line Oropharyngeal Squamous Cell Carcinoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Qyuns Therapeutics’ Partner Caldera to Merge with Synlogic in $278M Backed Deal, Advancing TL1A/IL-23p19 Bispecific Antibody for Inflammatory Bowel Disease

Company Drug

Buchang Pharmaceuticals Withdraws Efperepoetin Alfa Registration Application for CKD Anemia Due to Dossier Enhancement Requirements

Company Drug

Hengrui Pharmaceuticals’ HER3-Targeting ADC Ruzaltatug Rezetecan Receives NMPA Marketing Application Acceptance for EGFR-Mutant NSCLC Post-TKI Progression

Company Drug

Huahai Pharmaceutical’s Anti-IL-36R Antibody Huayijing Receives NMPA Priority Review Approval for Generalized Pustular Psoriasis Flares

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.